We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for sales and earnings is pegged at $527 million and 63 cents per share, respectively.
Exelixis’ Earnings Surprise History
Exelixis beat on earnings in each of the trailing four quarters, the average surprise being 48.6%. In the last reported quarter, the company beat on earnings by 47.62%.
Exelixis generates revenues from net product sales, license revenues and collaboration and service revenues.
Net product revenues have likely increased in the second quarter, driven by a rise in Cabometyx sales volumes and average net selling price.
Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma. The drug maintains its status as the leading TKI for RCC, both in the front-line IO+TKI market and the second-line monotherapy segment. The trend is likely to have continued in the second quarter.
In April 2025, the FDA approved the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).
Simultaneously, the drug was approved for adult and pediatric patients (12 years of age and older) with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Additional updates on the same are expected.
This label expansion of Cabometyx has likely resulted in its incremental sales.
The Zacks Consensus Estimate for sales of the drug is pegged at $527 million and our model estimate for the same is pinned at $511.3 million.
The board recently authorized the repurchase of up to an additional $500 million of the company’s common stock before Dec. 31, 2025. Exelixis plans to complete the currently ongoing $500 million stock repurchase program (announced in August 2024) in the second quarter of 2025 and commence repurchases under the newly authorized program thereafter.
The bottom line has likely gained from the ongoing share repurchases.
Operating expenses might have increased due to costs associated with the broader portfolio.
Apart from the quarterly performance, the focus is on pipeline updates. The company recently announced positive top-line results from the late-stage STELLAR-303 study.
Zanzalintinib is a third-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER.
The STELLAR-303 study met one of its dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) for the intent-to-treat (ITT) population when treated with zanzalintinib in combination with Tecentriq compared with the current standard-of-care drug, regorafenib.
Exelixis stated that the trial will continue to a final analysis of the second primary endpoint — OS in the subgroup without liver metastases (non-liver metastases, or NLM).
What Our Model Predicts for EXEL
Our proven model predicts an earnings beat for EXEL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below.
Earnings ESP: Earnings ESP for Exelixis is +2.52% as the Zacks Consensus Estimate is pegged at 63 cents per share, while the Most Accurate Estimate is pinned at 65 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Exelixis Price Performance
The company’s shares have gained 33.5% year to date against the industry's decline of 1.1%.
Image Source: Zacks Investment Research
Other Stocks to Consider
Here are some other stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this reporting cycle.
Akero Therapeutics ((AKRO - Free Report) ) has an Earnings ESP of +0.53% and a Zacks Rank #1 at present.
AKRO stock has surged 87% year to date. Akero beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 48.90%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte ((INCY - Free Report) ) has an Earnings ESP of +1.43% and a Zacks Rank #2 at present.
Shares of INCY have gained 16.3% in the past three months. INCY intends to report second-quarter earnings on July 29, before the opening bell.
Alkermes ((ALKS - Free Report) ) has an Earnings ESP of +4.94% and a Zacks Rank #3 at present.
ALKS will report second-quarter results on July 29, 2025. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Key Takeaways
Investors will focus on lead drug Cabometyx’ performance when Exelixis ((EXEL - Free Report) ) reports second-quarter 2025 results on July 28.
The Zacks Consensus Estimate for sales and earnings is pegged at $527 million and 63 cents per share, respectively.
Exelixis’ Earnings Surprise History
Exelixis beat on earnings in each of the trailing four quarters, the average surprise being 48.6%. In the last reported quarter, the company beat on earnings by 47.62%.
Exelixis, Inc. Price, Consensus and EPS Surprise
Exelixis, Inc. price-consensus-eps-surprise-chart | Exelixis, Inc. Quote
Factors at Play in Q2
Exelixis generates revenues from net product sales, license revenues and collaboration and service revenues.
Net product revenues have likely increased in the second quarter, driven by a rise in Cabometyx sales volumes and average net selling price.
Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma. The drug maintains its status as the leading TKI for RCC, both in the front-line IO+TKI market and the second-line monotherapy segment. The trend is likely to have continued in the second quarter.
In April 2025, the FDA approved the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).
Simultaneously, the drug was approved for adult and pediatric patients (12 years of age and older) with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Additional updates on the same are expected.
This label expansion of Cabometyx has likely resulted in its incremental sales.
The Zacks Consensus Estimate for sales of the drug is pegged at $527 million and our model estimate for the same is pinned at $511.3 million.
The board recently authorized the repurchase of up to an additional $500 million of the company’s common stock before Dec. 31, 2025. Exelixis plans to complete the currently ongoing $500 million stock repurchase program (announced in August 2024) in the second quarter of 2025 and commence repurchases under the newly authorized program thereafter.
The bottom line has likely gained from the ongoing share repurchases.
Operating expenses might have increased due to costs associated with the broader portfolio.
Apart from the quarterly performance, the focus is on pipeline updates. The company recently announced positive top-line results from the late-stage STELLAR-303 study.
Zanzalintinib is a third-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER.
The STELLAR-303 study met one of its dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) for the intent-to-treat (ITT) population when treated with zanzalintinib in combination with Tecentriq compared with the current standard-of-care drug, regorafenib.
Exelixis stated that the trial will continue to a final analysis of the second primary endpoint — OS in the subgroup without liver metastases (non-liver metastases, or NLM).
What Our Model Predicts for EXEL
Our proven model predicts an earnings beat for EXEL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below.
Earnings ESP: Earnings ESP for Exelixis is +2.52% as the Zacks Consensus Estimate is pegged at 63 cents per share, while the Most Accurate Estimate is pinned at 65 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Exelixis Price Performance
The company’s shares have gained 33.5% year to date against the industry's decline of 1.1%.
Image Source: Zacks Investment Research
Other Stocks to Consider
Here are some other stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this reporting cycle.
Akero Therapeutics ((AKRO - Free Report) ) has an Earnings ESP of +0.53% and a Zacks Rank #1 at present.
AKRO stock has surged 87% year to date. Akero beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 48.90%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte ((INCY - Free Report) ) has an Earnings ESP of +1.43% and a Zacks Rank #2 at present.
Shares of INCY have gained 16.3% in the past three months. INCY intends to report second-quarter earnings on July 29, before the opening bell.
Alkermes ((ALKS - Free Report) ) has an Earnings ESP of +4.94% and a Zacks Rank #3 at present.
ALKS will report second-quarter results on July 29, 2025. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%.